Active control trials: Endpoints beyond conventional efficacy and tolerability measures

Epilepsy Research

Volumn 68, Issue 1, 2006, Pages 73-74

  Perucca, Emilio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; LAMOTRIGINE;

CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; EPILEPSY; HEADACHE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; MOOD DISORDER; NEUROPATHIC PAIN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; SEIZURE; SLEEP DISORDER; TREATMENT OUTCOME;

AFFECT; ANTICONVULSANTS; COGNITION; EPILEPSY; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE;

EID: 30144436804     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2005.09.026     Document Type: Conference Paper

References (12)

1. D. Battino, M.N.G. Dukes, and E. Perucca Anticonvulsants M.N.G. Dukes J.K. Aronson Meyler's Side Effects of Drugs fourteenth ed. 2000 Elsevier Science B.V. Amsterdam 164 197
2. L.S. Boylan, L.A. Flint, D.L. Labovitz, S.C. Jackson, K. Starner, and O. Devinsky Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy Neurology 62 2004 258 261
3. S. Bramswig, T. Sudhop, C. Luers, K. Von Bergmann, and H.K. Berthold Lipoprotein-a concentration increases during treatment with carbamazepine Epilepsia 44 2003 457 460
4. J.A. Cramer, D. Blum, M. Reed, K. Fanning for the Epilepsy Impact Project Group The influence of comorbid depression on seizure severity Epilepsia 44 2003 1578 1584
5. J. Eiris Punal, M. Del Rio-Garma, M.C. Del Rio-Garma, S. Lojo-Rocamonde, I. Novo-Rodriguez, and M. Castro-Cago Long-term treatment of children with epilepsy with valproate and carbamazepine may cause subclinical hyperhyroidism Epilepsia 40 1999 1761 1766
6. E.K. Johnson, J.E. Jones, M. Seidenberg, and B.P. Hermann The relative impact of anxiety, depression, and clinical seizure features on health-related quality of life in epilepsy Epilepsia 45 2004 544 550
7. L.J. Hirsch, D. Weintraub, Y. Du, R. Buchsbaum, H.T. Spencer, M. Hager, T. Straka, C.W. Bazil, D.J. Adams, S.R. Resor Jr., and M.J. Morrell Correlating serum lamotrigine concentrations with tolerability in patients with epilepsy Neurology 63 2004 1022 1026
8. P.B. Pennell, D.J. Newport, Z.N. Stowe, S.L. Helmers, J.Q. Montgomery, and T.R. Henry The impact of pregnancy and childbirth on the metabolism of lamotrigine Neurology 62 2004 292 295
9. E. Perucca, and T. Tomson Monotherapy trials with the new antiepileptic drugs: study designs, practical relevance and ethical implications Epilepsy Res. 33 2000 247 262
10. E. Perucca, E. Beghi, S. Shorvon, and T. Tomson Assessing risk to benefit ratio in antiepileptic drug therapy Epilepsy Res. 41 2000 107 139
11. E. Perucca Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin. Pharmacokin. 38 2000 191 204
12. A. Sabers, I. Ohman, J. Christensen, and T. Tomson Oral contraceptives reduce lamotrigine plasma levels Neurology 6 2003 570 571